What You Should Know:
- Juno Diagnostics, a healthcare technology company developing the next generation cell-free DNA-based noninvasive prenatal test solutions announced it has ceased commercial operations, effective immediately.
- The company released a statement citing “unforeseen circumstances have led to this difficult decision, and we’re devastated that we can no longer continue our mission-driven work to support expectant mothers like you. As we wind down commercial operations, please know that our team is working diligently to ensure patient data is handled with the utmost care and privacy.”
- Juno Diagnostics was founded by an experienced team in 2017 that developed and launched the industry’s first NIPT (noninvasive prenatal testing test) product while at Sequenom. JunoDx’s product offerings for NIPT include a Fetal Gender Test and Pre-Natal Screening Test. The company raised $25M to date.
